<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/Newsletter/style.css"/>
<title>Summit Therapeutics&#x27; Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences â€” Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/Newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Summit Therapeutics&#x27; Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences</h2>
    <div class="badge">2025-09-08T12:28:07+00:00</div>
    <ul>
      <li>In September 2025, an additional analysis included longer-term follow-up of Western patients (median follow-up time of Western patients of 13.7 months).</li>
<li>4.4 months, respectively.</li>
<li>placebo plus chemotherapy was 6.8 months vs.</li>
<li>(NASDAQ:SMMT), on Sunday, revealed the updated overall survival (OS) results from the global Phase 3 HARMONi trial of ivonescimab at the 2025 World Conference on Lung Cancer (WCLC).</li>
<li>The statistical analysis plan for the study required a p-value of 0.0448 to achieve statistical significance.</li>
<li>Median overall survival was 16.8 months for ivonescimab plus chemotherapy versus 14.0 months for placebo plus chemotherapy.</li>
<li>Data showed a hazard ratio consistent with the primary analysis was observed with an improved nominal p-value (HR=0.78; nominal p=0.0332).</li>
    </ul>
    <p>
      <a class="btn" href="https://x.com/intent/tweet?text=Summit%20Therapeutics%27%20Lung%20Cancer%20Drug%20Under%20Dark%20Clouds%20As%20Keytruda%20Challenger%20Shows%20Regional%20Data%20Differences%0A%E2%80%A2%20In%20September%202025%2C%20an%20additional%20analysis%20included%20longer-term%20follow-up%20of%20Western%20patients%20%28median%20follow-up%20time%20of%20Western%20patients%20of%2013.7%20months%29.%0A%E2%80%A2%204.4%20months%2C%20respectively.%0A%E2%80%A2%20placebo%20plus%20chemotherapy%20was%206.8%20months%20vs.%0A%E2%80%A2%20%28NASDAQ%3ASMMT%29%2C%20on%20Sunday%2C%20revealed%20the%20updated%20overall%20survival%20%28OS%29%20results%20from%20the%20global%20Phase%203%20HARMONi%20trial%20of%20ivonescimab%20at%20the%202025%20World%20Conference%20on%20Lung%20Cancer%20%28WCLC%29.%0A%E2%80%A2%20The%20statistical%20analysis%20plan%20for%20the%20study%20required%20a%20p-value%20of%200.0448%20to%20achieve%20statistical%20significance.%0A%E2%80%A2%20Median%20overall%20survival%20was%2016.8%20months%20for%20ivonescimab%20plus%20chemotherapy%20versus%2014.0%20months%20for%20placebo%20plus%20chemotherapy.%0A%E2%80%A2%20Data%20showed%20a%20hazard%20ratio%20consistent%20with%20the%20primary%20analysis%20was%20observed%20with%20an%20improved%20nominal%20p-value%20%28HR%3D0.78%3B%20nominal%20p%3D0.0332%29.&url=https%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Fsummit-therapeutics-lung-cancer-drug-under-dark-clouds-as-keytruda-challenger-sh%2F" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a class="btn" href="https://finance.yahoo.com/news/summit-therapeutics-lung-cancer-drug-122807408.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>